Bob Hariri, M.D., Ph.D., is the vice chairman of Human Longevity Inc. (HLI), a genomics and cell-therapy diagnostics and therapeutics company he co-founded in 2013 with Craig Venter and Peter Diamandis, which is focused on extending the healthy, high-performance human lifespan. Utilizing technological advancements in genomics, bioinformatics, computing and cell therapy, HLI plans to develop therapeutic solutions to some of the most complex yet actionable diseases, such as cancer, heart disease and dementia. A recipient of the Thomas Alva Edison Award in 2007 and 2011, the former CEO of Celgene Cellular Therapeutics, and one of the pioneers of the global cell-therapy industry, Bob recently sat down with me to discuss his current work on the frontiers of aging and cellular science.
You've formed one of the most provocative and promising companies working in the cellular sciences. How did you get together with Craig Venter and Peter Diamandis of the X PRIZE?